Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2005

01-07-2005

Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery

Authors: Masaya Nomura, Yoshifumi Inoue, Shigeo Fujita, Jun Sakao, Masaki Hirota, Shigeo Souda, Masato Ohshima

Published in: Breast Cancer | Issue 3/2005

Login to get access
Metadata
Title
Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery
Authors
Masaya Nomura
Yoshifumi Inoue
Shigeo Fujita
Jun Sakao
Masaki Hirota
Shigeo Souda
Masato Ohshima
Publication date
01-07-2005
Publisher
Springer-Verlag
Published in
Breast Cancer / Issue 3/2005
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.2325/jbcs.12.226

Other articles of this Issue 3/2005

Breast Cancer 3/2005 Go to the issue

OriginalPaper

Prediction of early and late recurrence in patients with breast carcinoma

Report

A case of burkitt’s lymphoma involving both breasts

OriginalPaper

Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast

OriginalPaper

Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer

OriginalPaper

Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes

Report

Two cases with long-term disease-free survival after resection and radiotherapy for solitary brain metastasis from breast cancer with extensive nodal metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits